GlassScriptPhysician profile
James Keith Winstead
NPI 1467865006
$1,473.06
in general payments reported to CMS, 2019-2025
23 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $61.12 · 2021: $360 · 2022: $83.44 · 2023: $317 · 2024: $315 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.77 |
| Education | $218.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $373.48 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $299.89 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $79.94 | 2019-2024 | Gardasil 9, Gardasil |
| Coopersurgical, INC. | $76.57 | 2021 | |
| Pfizer INC. | $74.74 | 2023-2025 | |
| Organon LLC | $66.98 | 2021-2024 | |
| Hologic Sales and Service, LLC | $58.93 | 2019-2025 | Novasure, Myosure Tissue Removal Device |
| Intuitive Surgical, INC. | $52.25 | 2021 | |
| Sumitomo Pharma America, INC. | $51.56 | 2023-2025 | Myfembree |
| Sage Therapeutics, LLC | $48.59 | 2024-2025 | Zurzuvae |
| Vertex Pharmaceuticals Incorporated | $40.93 | 2024-2025 | |
| Medtronic, INC. | $38.97 | 2024 | Ligasure |
| Takeda Pharmaceuticals U.S.A., INC. | $38.87 | 2019-2021 | |
| Evofem Biosciences, INC. | $30.23 | 2021-2023 | Phexxi |
| Convatec INC. | $24.36 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $19.01 | 2025 | Perclot |
| Supernus Pharmaceuticals, INC. | $17.21 | 2025 | Qelbree |
| Therapeuticsmd, INC. | $16.16 | 2019 | |
| Avion Pharmaceuticals | $14.88 | 2022 | |
| Smith+Nephew, INC. | $13.70 | 2023 | Pico 7 |
| Agile Therapeutics, INC. | $12.75 | 2023 | Twirla |
| Coloplast Corp | $11.70 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Winstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.